IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice.

The development of an effective therapy for Alzheimer's disease (AD) is a major challenge to biomedical sciences. Because much of early AD pathophysiology includes hippocampal abnormalities, a viable treatment strategy might be to use trophic factors that support hippocampal integrity and funct...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tiffany J Mellott, Sarah M Pender, Rebecca M Burke, Erika A Langley, Jan Krzysztof Blusztajn
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d0b1f49616ee437895bfdb2fe02d6eae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d0b1f49616ee437895bfdb2fe02d6eae
record_format	dspace
spelling	oai:doaj.org-article:d0b1f49616ee437895bfdb2fe02d6eae2021-11-18T08:23:32ZIGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice.1932-620310.1371/journal.pone.0094287https://doaj.org/article/d0b1f49616ee437895bfdb2fe02d6eae2014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24732467/?tool=EBIhttps://doaj.org/toc/1932-6203The development of an effective therapy for Alzheimer's disease (AD) is a major challenge to biomedical sciences. Because much of early AD pathophysiology includes hippocampal abnormalities, a viable treatment strategy might be to use trophic factors that support hippocampal integrity and function. IGF2 is an attractive candidate as it acts in the hippocampus to enhance memory consolidation, stimulate adult neurogenesis and upregulate cholinergic marker expression and acetylcholine (ACh) release. We performed a seven-day intracerebroventricular infusion of IGF2 in transgenic APPswe.PS1dE9 AD model mice that express green fluorescent protein in cholinergic neurons (APP.PS1/CHGFP) and in wild type WT/CHGFP littermates at 6 months of age representing early AD-like disease. IGF2 reduced the number of hippocampal Aβ40- and Aβ42-positive amyloid plaques in APP.PS1/CHGFP mice. Moreover, IGF2 increased hippocampal protein levels of the ACh-synthesizing enzyme, choline acetyltransferase in both WT/CHGFP and APP.PS1/CHGFP mice. The latter effect was likely mediated by increased protein expression of the cholinergic differentiating factor, BMP9, observed in IGF2-treated mice as compared to controls. IGF2 also increased the protein levels of hippocampal NGF, BDNF, NT3 and IGF1 and of doublecortin, a marker of neurogenesis. These data show that IGF2 administration is effective in reversing and preventing several pathophysiologic processes associated with AD and suggest that IGF2 may constitute a therapeutic target for AD.Tiffany J MellottSarah M PenderRebecca M BurkeErika A LangleyJan Krzysztof BlusztajnPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 4, p e94287 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Tiffany J Mellott Sarah M Pender Rebecca M Burke Erika A Langley Jan Krzysztof Blusztajn IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice.
description	The development of an effective therapy for Alzheimer's disease (AD) is a major challenge to biomedical sciences. Because much of early AD pathophysiology includes hippocampal abnormalities, a viable treatment strategy might be to use trophic factors that support hippocampal integrity and function. IGF2 is an attractive candidate as it acts in the hippocampus to enhance memory consolidation, stimulate adult neurogenesis and upregulate cholinergic marker expression and acetylcholine (ACh) release. We performed a seven-day intracerebroventricular infusion of IGF2 in transgenic APPswe.PS1dE9 AD model mice that express green fluorescent protein in cholinergic neurons (APP.PS1/CHGFP) and in wild type WT/CHGFP littermates at 6 months of age representing early AD-like disease. IGF2 reduced the number of hippocampal Aβ40- and Aβ42-positive amyloid plaques in APP.PS1/CHGFP mice. Moreover, IGF2 increased hippocampal protein levels of the ACh-synthesizing enzyme, choline acetyltransferase in both WT/CHGFP and APP.PS1/CHGFP mice. The latter effect was likely mediated by increased protein expression of the cholinergic differentiating factor, BMP9, observed in IGF2-treated mice as compared to controls. IGF2 also increased the protein levels of hippocampal NGF, BDNF, NT3 and IGF1 and of doublecortin, a marker of neurogenesis. These data show that IGF2 administration is effective in reversing and preventing several pathophysiologic processes associated with AD and suggest that IGF2 may constitute a therapeutic target for AD.
format	article
author	Tiffany J Mellott Sarah M Pender Rebecca M Burke Erika A Langley Jan Krzysztof Blusztajn
author_facet	Tiffany J Mellott Sarah M Pender Rebecca M Burke Erika A Langley Jan Krzysztof Blusztajn
author_sort	Tiffany J Mellott
title	IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice.
title_short	IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice.
title_full	IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice.
title_fullStr	IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice.
title_full_unstemmed	IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice.
title_sort	igf2 ameliorates amyloidosis, increases cholinergic marker expression and raises bmp9 and neurotrophin levels in the hippocampus of the appsweps1de9 alzheimer's disease model mice.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/d0b1f49616ee437895bfdb2fe02d6eae
work_keys_str_mv	AT tiffanyjmellott igf2amelioratesamyloidosisincreasescholinergicmarkerexpressionandraisesbmp9andneurotrophinlevelsinthehippocampusoftheappsweps1de9alzheimersdiseasemodelmice AT sarahmpender igf2amelioratesamyloidosisincreasescholinergicmarkerexpressionandraisesbmp9andneurotrophinlevelsinthehippocampusoftheappsweps1de9alzheimersdiseasemodelmice AT rebeccamburke igf2amelioratesamyloidosisincreasescholinergicmarkerexpressionandraisesbmp9andneurotrophinlevelsinthehippocampusoftheappsweps1de9alzheimersdiseasemodelmice AT erikaalangley igf2amelioratesamyloidosisincreasescholinergicmarkerexpressionandraisesbmp9andneurotrophinlevelsinthehippocampusoftheappsweps1de9alzheimersdiseasemodelmice AT jankrzysztofblusztajn igf2amelioratesamyloidosisincreasescholinergicmarkerexpressionandraisesbmp9andneurotrophinlevelsinthehippocampusoftheappsweps1de9alzheimersdiseasemodelmice
_version_	1718421891153133568

IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice.

Ejemplares similares